Leukemia Therapeutics Market Report 2026

Leukemia Therapeutics Market Overview

• Leukemia Therapeutics market size has reached to $18.67 billion in 2025 • Expected to grow to $27.41 billion in 2030 at a compound annual growth rate (CAGR) of 8% • Growth Driver: The Impact Of Increasing Leukemia Prevalence On The Leukemia Therapeutics Market • Market Trend: Innovative Advancements In The Leukemia Therapeutics Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Leukemia Therapeutics Market?

Leukemia therapeutics refer to a treatment used to treat an aggressive (quickly spreading) malignancy in which the blood or bone marrow contain an excessive amount of myeloblasts (immature white blood cells). The type treatment for leukemia depends on various factors such as age, overall health, type of leukemia, its current condition within the body and others. The main treatment types in leukemia therapeutics are chemotherapy, immunotherapy, targeted therapy, and other treatments. Immunotherapy is a method of leukemia treatment that stimulates the body's immune system to recognize and eliminate malignant cells. These are used to treat acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and other types of leukemia using small molecules and biologics. The various end users of leukemia therapeutics are hospitals, homecare, specialty clinics, and other end-users.

What Is The Leukemia Therapeutics Market Growth Forecast?

The leukemia therapeutics market size is expected to see strong growth in the next few years. It will grow to $27.41 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to expansion of CAR T-cell therapies, adoption of precision medicine approaches, integration of AI in treatment planning, growth in homecare treatment solutions, development of novel targeted therapies. Major trends in the forecast period include personalized leukemia treatment, advanced diagnostic integration, outpatient and home-based therapy expansion, combination therapy development, rare and resistant leukemia focus.

Global Leukemia Therapeutics Market Segmentation

1) By Treatment Type: Chemotherapy, Immunotherapy, Targeted Therapy, Other Treatments 2) By Type Of Leukemia: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Type Of Leukemia 3) By Molecule Type: Small Molecules, Biologics 4) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users Subsegments: 1) By Chemotherapy: Alkylating Agents, Antimetabolites, Plant Alkaloids, Corticosteroids 2) By Immunotherapy: Monoclonal Antibodies, CAR T-Cell Therapy, Immune Checkpoint Inhibitors, Vaccines 3) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), BCL-2 Inhibitors, IDH Inhibitors, Other Targeted Agents 4) By Other Treatments: Radiation Therapy, Stem Cell Transplantation, Supportive Care Treatments

What Is The Driver Of The Leukemia Therapeutics Market?

The rising prevalence of leukemia is driving the growth of the leukemia therapeutics market. Leukemia is a type of blood cancer that starts in the bone marrow and proceeds to uncontrolled blood cell growth. The increased accessibility of medical treatment to leukemia patients across the globe and the growing availability of treatment options have contributed to increased demand for leukemia therapeutics. For instance, in January 2023, according to a report published by the American Cancer Society, a US-based health organization, it is anticipated that there will be around 59,610 new instances of leukemia of all types and approximately 23,710 fatalities in 2023 resulting from leukemia of all types in the United States. Additionally, an estimated 20,380 new cases of acute myeloid leukemia (AML) and about 11,310 AML-related deaths are expected in the same year. Therefore, the rising prevalence of leukemia is contributing to the growth of the leukemia therapeutics industry.

Key Players In The Global Leukemia Therapeutics Market

Major companies operating in the leukemia therapeutics market are Novartis International AG, AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Sanofi S. A., Agios Pharmaceuticals, Amgen Inc., Argenx SE, Astellas Pharma Inc., BioLineRx Ltd., Cellerant Therapeutics Inc., Daiichi Sankyo Company Limited, Forma Therapeutics Inc., Gilead Sciences Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Johnson & Johnson, Mirati Therapeutics Inc., Molecular Templates Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Seattle Genetics Inc., Stemline Therapeutics Inc., Sunesis Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, TG Therapeutics Inc., Allogene Therapeutics Inc., Blueprint Medicines Corporation, Karyopharm Therapeutics Inc., Verastem Oncology Inc.

Global Leukemia Therapeutics Market Trends and Insights

Major companies operating in the leukemia therapeutics market are developing innovative products such as CAR T therapies to meet larger customer bases, increase sales, and increase revenue. Chimeric Antigen Receptor T-cell (CAR-T) therapy is a groundbreaking form of immunotherapy for the treatment of certain types of cancer. For instance, in March 2024, Bristol-Myers Squibb Company, a US-based pharmaceutical company, announced the US Food and Drug Administration (FDA) approval for Breyanzi (lisocabtagene maraleucel; liso-cel). This therapy is a CD19-directed chimeric antigen receptor (CAR) T cell treatment designed for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have undergone at least two previous lines of therapy, including both a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.

What Are Latest Mergers And Acquisitions In The Leukemia Therapeutics Market?

In February 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for an undisclosed amount. The acquisition enhances AstraZeneca’s expanding pipeline of cell therapies by adding GC012F, a novel clinical-stage FasTCAR-enabled autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets both BCMA and CD19. Gracell will function as a wholly owned subsidiary of AstraZeneca, maintaining operations in both China and the United States. Gracell Biotechnologies Inc. is a China-based biopharmaceutical company that specializes in cell therapies for leukemia and autoimmune diseases.

Regional Insights

North America was the largest region in the leukemia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Leukemia Therapeutics Market?

The leukemia therapeutics market includes revenues earned by entities by killing fast-growing cancer cells. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Leukemia Therapeutics Market Report 2026?

The leukemia therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the leukemia therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.